Oncolytic Single-Cycle Replicating Immunotherapies for Kidney Cancer
Abstract
Treatments for kidney cancer have improved, but there are still many patients who ultimately succumb to the disease. New immune therapies are being developed to activate the immune system to kill cancer cells. While these are promising, these new therapies are very expensive and may cost patients $150,000 to more than 1 million dollars per year. This project aims to develop a cheaper approach using viruses to carry immune-stimulating proteins. The goal is to deliver proteins that can activate the kidney patients own immune system to hunt down and kill local or metastatic tumor cells. This project will test these immune system stimulators in animals by injecting the therapy directly into the kidney. We will determine if stimulating different immune cells is more effective at controlling kidney cancer cells. If this is effective, it can be deployed for kidney cancer patients by injecting the therapies directly into the kidney or by injection into the blood stream.
Document Details
- Document Type
- DoD Grant Award
- Publication Date
- Nov 19, 2019
- Source ID
- W81XWH1910756
Entities
People
- Michael A Barry
Organizations
- Mayo Clinic
- United States Army